Type of non Hodgkin's lymphoma-Other-Primary mediastinal large B-cell lymphoma - Page 2 of 2 Posts on Medivizor
Navigation Menu

Type of non Hodgkin’s lymphoma-Other-Primary mediastinal large B-cell lymphoma Posts on Medivizor

Evaluating the impact of adding combination antiretroviral therapy to chemotherapy in HIV-positive patients with non-Hodgkin’s lymphoma

Posted by on Sep 8, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the outcomes of concurrent (at the same time) combination antiretroviral therapy (cART) and chemotherapy in HIV-positive patients with non-Hodgkin’s lymphoma (NHL). This study concluded that concurrent cART with chemotherapy was well-tolerated and allowed for faster immune recovery in these patients, but did not...

Read More

Evaluating the outcomes after second-line therapy for relapsed or refractory PMBCL

Posted by on Aug 17, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the outcomes of pretreated patients with relapsed (cancer recurrence) or refractory (does not respond to treatment) primary mediastinal large B-cell lymphoma (PMBCL) after second-line therapy and stem cell transplant (SCT). The study concluded that this treatment strategy was effective in most patients. Some...

Read More

Radiotherapy for relapsed or refractory diffuse large b-cell lymphoma

Posted by on May 29, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effectiveness of consolidative or salvage radiotherapy for patients with relapsed or refractory (does not respond to treatment) diffuse large B-cell lymphoma. This study concluded that radiotherapy is an effective option for high-risk patients. Some background The most widely used treatment for diffuse large...

Read More

Looking for patients with relapsed B-cell non-Hodgkin’s lymphoma to test the effectiveness of a copanlisib and rituximab combination treatment

Posted by on Sep 12, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This phase 3 clinical trial will evaluate the safety and effectiveness of a copanlisib (BAY 80-6946) and rituximab (Rituxan) combination in treating patients with relapsed indolent B-cell non-Hodgkin’s lymphoma (iNHL). The primary outcome will be measured by time to disease progression. The details Copanlisib is an inhibitor of...

Read More

Looking for patients to test the effectiveness of chemotherapy and rituximab combination in treating non-Hodgkin’s lymphoma

Posted by on Aug 21, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This phase 2 clinical trial  will test the effectiveness of EPOCH, a 5-drug combination chemotherapy, with rituximab (Rituxan) in patients with certain types of non-Hodgkin's lymphoma. The primary outcome will be measured by the overall response and time to disease progression. This trial is being conducted in Maryland, in the...

Read More